托拉塞米治疗射血分数中间值心衰的临床疗效分析

Clinical Efficacy of Torasemide in the Treatment of Heart Failure with Median Ejection Fraction

目的研究托拉塞米治疗射血分数中间值心衰的临床疗效。方法选择合肥市第二人民医院心血管内科的射血分数中间值心衰患者作为该次研究对象,收取时间在2017年1月-2019年1月,根据其入院顺序对其进行分组,将100例患者进行分组,主要包括两组,其中观察组实施托拉塞米治疗;对照组实施呋塞米治疗,将两组治各项指标进行对比。结果观察组患者治疗总有效率86.00%高于对照组(χ~2=4.574,P<0.05);观察组患者NT-proBNP (421.35±1.00)pg/mL、PRA (1.51±0.02)ng/mL、Ang/II(135.21±1.32)pg/mL、ALD (172.22±1.01)pg/mL均低于对照组(t=420.082、5.265、93.832、94.323,P<0.05);观察组患者LVEF(49.21±3.45)%、LVEDD (49.21±1.03)mm、LVESD (40.21±9.15)mm、LAD (30.12±5.01)mm指标和对照组,差异有统计学意义(t=6.999、25.495、5.186、5.935,P<0.05);观察组6MWT(345.21±39.11)m、 MLWHF(45.21±7.51)m指标和对照组比较,差异有统计学意义(t=8.085、4.220,P<0.05)。观察组不良反应发生率8.00%低于对照组(χ~2=3.843,P<0.05)。结论托拉塞米治疗射血分数中间值心衰的临床疗效十分显著。

Objective To study the clinical efficacy of torasemide in the treatment of ejection fraction median heart failure. Methods The patients with heart failure with median ejection fraction in cardiovascular medicine department of Hefei Second People’s Hospital were selected as the research object. The patients were collected from January 2017 to January 2019. They were grouped according to their admission order. 100 patients were grouped into two groups, including two groups. The observation group was treated with tolasemide. The control group was treated with furosemide, and the indexes of the two groups were compared. Results The total effective rate of treatment in the observation group was 86.00% higher than that in the control group(χ~2=4.574, P<0.05,);in the observation group, NT-proBNP(421.35±1.00) pg/mL, PRA(1.51±0.02) ng/mL, Ang/II(135.21±1.32) pg/mL and ALD(172.22±1.01) pg/mL were lower than the control group(t=420.082, 5.265, 93.832, 94.323,P<0.05). The observation group had LVEF(49.21±3.45)%, LVEDD(49.21±1.03) mm, LVESD(40.21±9.15) mm, LAD(30.12±5.01) mm and the control group, the difference was statistically significant(t=6.999, 25.495, 5.186, 5.935, P<0.05);observation group 6 MWT(345.21 ± 39.11) m, MLWHF(45.21±7.51)m index and control group, the difference was statistically significant(t=8.085, 4.220, P<0.05). The incidence of adverse reactions in the observation group was 8.00% lower than that in the control group(χ~2=3.843, P<0.05). Conclusion Torasemide is effective and safe in the treatment of ejection fraction median heart failure. It can improve the clinical indicators of patients and is worthy of research and promotion.